Key result
A Random Forest machine learning model incorporating ticagrelor exposure and clinical variables predicted bleeding risk in Chinese patients with acute coronary syndrome with an ROC-AUC of 0.81.
Why the study?
Ticagrelor exposure is higher in East Asians compared with White populations, leading to an increased risk of bleeding.
Can a machine learning-based population pharmacokinetic model predict bleeding risk and inform ticagrelor dosing in Chinese patients with acute coronary syndrome?
Can a machine learning-based population pharmacokinetic model predict bleeding risk and inform ticagrelor dosing in Chinese patients with acute coronary syndrome?
Effect estimate: ROC-AUC 0.81
A machine learning-based population pharmacokinetic model can predict bleeding risk to help optimize ticagrelor dosing in Chinese patients with acute coronary syndrome.
Model may guide ticagrelor dosing in Chinese ACS patients; leaves open prospective validation before practice change.
The exposure to ticagrelor (BRILINTA) is higher in the East Asian population compared with the White population, thus, East Asians have an increased risk of bleeding. We developed a population pharmacokinetic (PopPK) model of ticagrelor based on a randomized 3 × 3 crossover study in healthy subjects. The area under the concentration-time curve (AUC) of Chinese patients with acute coronary syndrome was simulated based on this model. Following this, eight machine learning (ML) methods were used to construct bleeding risk models. Variables included in the final bleeding risk model were age, hypertension, body weight, AUC, drinking status, calcium channel blockers, antidiabetic medications, β-blockers, peripheral vascular disease, diabetes, transient ischemic attack, sex, and proton pump inhibitor. In terms of F1 scores and area under the curve of receiver operating characteristic curve (ROC-AUC), the Random Forest model performed best among all models, with an F1 score of 0.73 and ROC-AUC of 0.81. Moreover, the PopPK model and ML algorithm were used to bridge the real-world data to build a bleeding risk prediction model based on drug exposure and clinical information. Using this model, a ticagrelor regimen that is associated with a lower risk of bleeding in individuals can be obtained. This model should be further validated prospectively in clinical settings.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2023) studied Acute Coronary Syndrome. Ticagrelor was evaluated on Bleeding risk prediction model performance (ROC-AUC) (ROC-AUC 0.81). A Random Forest machine learning model incorporating ticagrelor exposure and clinical variables predicted bleeding risk in Chinese patients with acute coronary syndrome with an ROC-AUC of 0.81.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: